April 27, 2016
(Nature) – The itinerant lifestyle doesn’t seem to have hampered the microbiologist as she has carefully dissected the systems by which bacteria control their genomes. Charpentier is now acknowledged as one of the key inventors of the gene-editing technology known as CRISPR–Cas9, which is revolutionizing biomedical researchers’ ability to manipulate and understand genes. This year, she has already won ten prestigious science prizes, and has officially taken up a cherished appointment as a director of the Max Planck Institute for Infection Biology in Berlin. The gene-therapy company that she co-founded in 2013, CRISPR Therapeutics, has become one of the world’s most richly financed preclinical biotech companies, and she is in the middle of a high-profile patent dispute over the technology.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.